Pacing therapy for CHF (congestive heart failure) shows long-term promise
This article was originally published in Clinica
Medtronic's pacing therapy for congestive heart failure (CHF) has shown promise as a long-term treatment for patients with the debilitating condition, according to one-year follow-up data from a Canadian and European clinical trial.
You may also be interested in...
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.
FDA has little in the way of good information it can list on its CBD policy agenda so far, says Principal Deputy Commissioner Amy Abernethy. At recent regulatory conference, she said, "Like it or not, there is a massive human experiment going on right now. There’s CBD in most different product categories and people of many different backgrounds with potential vulnerabilities taking CBD."
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.